WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results for the first quarter of 2009. For the three months ended March 31, 2009, the Company reported a net loss of $15.2 million, or $(0.19) per share. This compares to a net loss of $12.0 million, or $(0.18) per share, for the first quarter of 2008. For the three months ended March 31, 2009, net cash used in operating activities was $11.9 million. Cash, cash equivalents and investments in marketable securities as of March 31, 2009 totaled $72.5 million. Additionally, subsequent to March 31, 2009, the Company received net proceeds of approximately $46.8 million from an underwritten public offering of its common stock.
